[ad_1]
On the particular importance of the new announcement of the Pfizer / BioNTech companies for the coronavirus vaccine reported by Elias Mosialos, Professor of Health Policy at LSE.
In a post on social networks, he explains, among other things, why the action of the vaccine is not only protective against mild diseases, characterizing the news extremely well and waiting for the data to be published in scientific journals.
Your publication in detail:
“With today’s announcement, and after re-analysis of their vaccine clinical trial data, Pfizer / BioNTech determine the effectiveness of their vaccine at 95% (of the 90% they initially announced).
95% results from the general results of the study. Of the 170 confirmed cases of participants who became ill, 162 were seen in patients who had received the placebo vaccine. Only 8 out of 170 had been vaccinated with the Covid-19 vaccine.
In addition, this time there was a report of cases in which the participants developed a serious disease: only one of the vaccinated study participants developed a serious disease in the 10 cases observed.
This is also very important because it means that the action of the vaccine not only protects against minor illnesses.
Excellent news that I hope will be confirmed by the publication of the data in scientific journals ”.
at google news and be the first to know all the news
[ad_2]
